Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Antimicrobial Agents and Chemotherapy|May 17, 2024
Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participantsMichael R Hodges, Sjoerd van Marle, William G Kramer, et al.Journal of Medical Virology|May 13, 2015
MicroRNA-122 associates with serum apolipoprotein B but not liver fibrosis markers in CHC genotype 1 infectionTzu-Hao Lee, Bassem Matta, Bernard D King, et al.Antimicrobial Agents and Chemotherapy|March 29, 2024
Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participantsMichael R Hodges, Susan Hazel, William G Kramer, et al.Antimicrobial Agents and Chemotherapy|July 16, 2024
A phase 1 open label study to assess the human mass balance and metabolite profile of <sup>14</sup>C-fosmanogepix, a novel Gwt-1 inhibitor in healthy male participantsMichael R Hodges, Eric Ople, Philip Evans, et al.The Journal of Antimicrobial Chemotherapy|September 8, 2023
Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropeniaOliver A Cornely, Helmut Ostermann, Philipp Koehler, et al.Antimicrobial Agents and Chemotherapy|December 28, 2020
Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of <i>Candida</i> Endophthalmitis and Hematogenous Meningoencephalitis in Nonneutropenic RabbitsRuta Petraitiene, Vidmantas Petraitis, Bo Bo Win Maung, et al.Antimicrobial Agents and Chemotherapy|April 6, 2023
Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris<i>:</i> Results from a Phase 2 TrialJose A Vazquez, Peter G Pappas, Kenneth Boffard, et al.Antimicrobial Agents and Chemotherapy|March 29, 2023
Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy VolunteersMichael R Hodges, Eric Ople, Pamela Wedel, et al.Antimicrobial Agents and Chemotherapy|November 12, 2014
In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122Søren Ottosen, Todd B Parsley, Lu Yang, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 9, 2013
Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9Eveline P van Poelgeest, Reinout M Swart, Michiel G H Betjes, et al.Pageof 2